TQB2930 not checked

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
4 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“TQB2930 injection is a HER2 bispecific antibody drug; Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.”In the company’s words, NCT07047365 on ClinicalTrials.gov
Tested for
HER2-positive Advanced Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies, Colorectal Cancer, Advanced Solid Tumor
Main trialPhase 3
“TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.”In the company’s words, NCT07047365 on ClinicalTrials.gov

Other drugs for HER2-positive Advanced Breast Cancer

All 397 drugs for HER2-positive Advanced Breast Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jun 2028 TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Phase 1/2Recruiting Dec 2026 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Phase 1/2Recruiting Jun 2027 A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
Phase 1/2Recruiting Mar 2028 Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Phase 1Unknown Apr 2023 Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TQB2930

Following is part of Solo: you see every change to TQB2930 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in